TLX591-Tx: Development overview and data highlights

27 February 2026

As a resource for analysts and investors, Telix has published a clinical data summary for TLX591-Tx (lutetium-177 rosopatamab tetraxetan), its investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC). The summary covers established dosimetry, safety, and efficacy data from the ProstACT SELECT Phase 1 study and prior clinical studies, as well as the design of the ongoing ProstACT GLOBAL Phase 3 trial.

View the full clinical data summary here

TLX591-TX has not received a marketing authorization in any jurisdiction.